RhumbLine Advisers’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

RhumbLine Advisers’s Portfolio PHAS Stock Details PHAS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-10,492	Closed	-$36K	–	3160
2021 Q1	$36K	Hold	10,492	–	–	﹤0.01%	2983
2020 Q4	$35K	Buy	+10,492	New	+$37.6K	﹤0.01%	3030
2020 Q3	–	Sell	-11,932	Closed	-$55K	–	3056
2020 Q2	$55K	Buy	+11,932	New	+$52.8K	﹤0.01%	3029
2019 Q4	–	Sell	-10,182	Closed	-$42K	–	2948
2019 Q3	$42K	Sell	10,182 -125	-1%	-$997	﹤0.01%	2934
2019 Q2	$135K	Buy	+10,307	New	+$126K	﹤0.01%	2878

Other funds holding PHAS

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

ECM

Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

JJIJ

Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return

ACM

Altium Capital Management New York $42M AUM

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

RhumbLine Advisers's PHAS Position: Q2 2021 in Review

RhumbLine Advisers sold out of PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q2 2021, closing a stake of 10,492 shares — an estimated $36K sold.

RhumbLine Advisers first reported a position in PHAS in Q2 2019 and held it in 5 quarters. The position peaked at $135K in Q2 2019. 55 funds tracked by Wall St. Rank hold PHAS as of Q2 2021.

RhumbLine Advisers reported no remaining PhaseBio Pharmaceuticals, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
RhumbLine Advisers sold 10,492 PhaseBio Pharmaceuticals, Inc. Common Stock shares in Q2 2021, an estimated $36K.
RhumbLine Advisers first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q2 2019 and held it in 5 quarters.
RhumbLine Advisers's PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $135K in Q2 2019.
55 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q2 2021.

Based on RhumbLine Advisers's 13F filing for Q2 2021, filed 5 Aug 2021.